Randomized phase II trials: Time for a new era in clinical trial design

Journal of Thoracic Oncology

Volumn 5, Issue 7, 2010, Pages 932-934

  Mandrekar, Sumithra J ^a   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

Author keywords

False negative; False positive; Phase II; Randomized; Screening; Selection

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; IRINOTECAN; MITOMYCIN C; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FINANCIAL MANAGEMENT; GASTROESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GASTROINTESTINAL CARCINOMA; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; PATIENT ASSESSMENT; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; TREATMENT RESPONSE; METHODOLOGY; NEOPLASMS; PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; NEOPLASMS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77954420205     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e2eadf     Document Type: Article

References (11)

1. Taylor JMG, Braun TM, Li Z. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm phase II design. Clin Trials 2006;3:335-338. (Pubitemid 44645824)
2. Wieand HS. Randomized phase II trials: what does randomization gain? J Clin Oncol 2005;23:1794-1795.
3. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23:7199-7206. (Pubitemid 46260307)
4. Rubinstein L, Crowley J, Ivy P, et al. Randomized phase II designs. Clin Cancer Res 2009;15:1883-1890.
5. Simon R, Wittes RE, Ellenberg SE. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381. (Pubitemid 16163075)
6. Sargent DJ, Goldberg RM. A flexible design for multiple armed screening trials. Stat Med 2001;20:1051-1060.
7. Steinberg SE, Venzon DJ. Early selection in a randomized phase II clinical trial. Stat Med 2002;21:1711-1726. (Pubitemid 34678902)
8. Lustberg MB, Bekaii-Saab T, Young D, et al. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinote-can in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol 2010;5:713-718.
9. Mandrekar SJ, Sargent DJ. Pick the winner designs in phase II cancer clinical trials. J Thorac Oncol 2006;1:5-6. (Pubitemid 47164014)
10. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191. (Pubitemid 41095154)
11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)